Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-2327-2025Class I

RELIANCE 4-FRONT, endocardial cardioversion/defibrillation and pace/sense lead, Permanent Defibrillator...

Boston Scientific Corporation / initiated 2025-07-24 / Open, Classified / root cause: design

Boston Scientific Corporation began a recall of RELIANCE 4-FRONT, endocardial cardioversion/defibrillation and pace/sense lead, Permanent Defibrillator Electrodes; Model Nos. 0654, 0655, 0657, 0658, 0682... on . FDA classified it as Class I and gives the reason as "Affected lead models may experience gradually rising LVSI measurements in association with calcification of the defibrillation lead coils. The issue may lead to early lead replacement. Most serious harm is death or need...". As of , the recall status on record is Open, Classified, and MDM tags the root cause as design.

Recall record

Recall number
Z-2327-2025
Classification
Class I
Status
Open, Classified
Initiated
Posted
Recalling firm
Boston Scientific Corporation
Product
RELIANCE 4-FRONT, endocardial cardioversion/defibrillation and pace/sense lead, Permanent Defibrillator Electrodes; Model Nos. 0654, 0655, 0657, 0658, 0682, 0683, 0685, 0686, 0692, 0693, 0695, 0696
Product code
NVY Permanent Defibrillator Electrodes
Reason for recall
Affected lead models may experience gradually rising LVSI measurements in association with calcification of the defibrillation lead coils. The issue may lead to early lead replacement. Most serious harm is death or need for cardiac resuscitation.
Root cause tag
design
FDA root cause
Component design/selection
Action
On July 24, 2025, firm notified physicians via Important Medical Device Information letters. The letter provides information on the management of gradually rising daily subthreshold, low-voltage shock impedance (LVSI) pattern associated with calcification of expanded polytetrafluoroethylene (ePTFE) coated single coil (SC) and dual coil (DC) RELIANCE defibrillation leads manufactured by Boston Scientific Corporation between 2002 to 2021. Letter includes recommendations for routine follow-ups of affected leads, and considerations to take if lead replacement is planned. The firm is not recommending any changes to the scheduled follow-up interval for patients with ePTFE lead models.
Quantity in commerce
247,702 US; 344,670 OUS
Distribution
Worldwide Distribution. US nationwide. International distribution worldwide.
Product codes and lots
Model 0657 UDI-DI 00802526560934; Model 0682 UDI-DI 00802526560958; Model 0683 UDI-DI 00802526560965; Model 0685 UDI-DI 00802526560972; Model 0686 UDI-DI 00802526560989; Model 0692 UDI-DI 00802526519017 00802526560996 00802526568664 00802526568688; Model 0693 UDI-DI 00802526518850 00802526519055 00802526537769 00802526561009 00802526568701; Model 0695 UDI-DI 00802526519093 00802526561016; Model 0696 UDI-DI 00802526519987 00802526561207 00802526568831

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-2327-2025
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-2325-2025Class IOngoingVoluntary: Firm initiated
Z-2326-2025Class IOngoingVoluntary: Firm initiated
Z-2327-2025Class IOngoingVoluntary: Firm initiated